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A SOCS1/3 Antagonist Peptide
Protects Mice Against Lethal
Infection with Influenza A Virus
Chulbul M. Ahmed*, Rea Dabelic, Simone Kennedy Bedoya, Joseph Larkin III and
Howard M. Johnson
Department of Microbiology and Cell Science, University of Florida, Gainesville, FL, USA
We have developed an antagonist to suppressor of cytokine signaling 1 (SOCS1),
pJAK2(1001–1013), which corresponds to the activation loop of the Janus kinase JAK2,
which is the binding site for the kinase inhibitory region (KIR) of SOCS1. Internalized
pJAK2(1001–1013) inhibits SOCS1 and SOCS3. SOCS1 has been shown to be an
influenza virus-induced virulence factor that enhances infection of cells. The antagonist
was protective in cell culture and in influenza virus PR8 lethally infected C57BL/6 mice.
The SOCS antagonist also prevented adversemorbidity as assessed by parameters, such
as weight loss and drop in body temperature, and showed potent induction of both the
cellular and humoral immune responses to the influenza virus candidate universal antigen
matrix protein 2 (M2e). The SOCS antagonist, thus, protectedmice against lethal influenza
virus infection and possessed potent adjuvancy against the M2e candidate influenza virus
universal vaccine antigen.
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INTRODUCTION
The process of activation of cells by cytokines, such as the interferons (IFNs), in response to viral
infections also activates an inducible cytokine regulatory system called suppressors of cytokine
signaling (SOCS). There are currently eight known members of the SOCS family, SOCS1 to
SOCS7 and cytokine-inducible Src homology 2 (SH2) protein (1). SOCS1 plays a central role
in regulation of IFN signaling via inhibition of JAK/STAT signaling. The N terminus of SOCS1
contains an SH2 domain, and N-terminal to it is an extended SH2 sequence adjacent to a kinase
inhibitory region (KIR). These regions or domains of SOCS1 bind to the activation and catalytic
regions of JAK2 and block its function. The C terminus of SOCS1 contains a domain called the
SOCS box, which is involved in proteasomal degradation of JAK2. We have shown that the KIR
sequence of SOCS1 binds to a peptide corresponding to the phosphorylated activation loop of JAK2,
pJAK2(1001–1013), and demonstrated that internalized pJAK2(1001–1013) blocked SOCS1 activity
in cells (2, 3). Specifically, pJAK2(1001–1013) enhances suboptimal IFN activity, blocks SOCS1-
induced inhibition of STAT3 activation, enhances IFNγ activation site (GAS) promoter activity, and
enhances antigen-specific proliferation. It is, thus, a potential antiviral therapeutic.
There is a dynamic interaction between the JAK kinases that mediate the antiviral effects of IFNs
and the IFN-induced SOCSmolecules (such as SOCS1), which prevents unregulated IFNactivity (4).
Along with the well-known induction of IFN in cells, there is also the constitutive or endogenous
presence of IFNβ, which interacts in complex ways with other IFNs in the induction of antiviral
states and other functions (5, 6). Specifically, endogenous IFNβ is the key to enhancing the biological
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activity of induced and added IFNαs and IFNγ (5, 6). SOCS1
antagonist administered intracellularly enhances endogenous
IFNβ levels by blocking the activity of both basal and induced
SOCS1 (3). Thus, SOCS1 antagonist enhances IFN activity.
We have previously shown that pJAK2(1001–1013) antago-
nized the IFN inhibitory effect of SOCS1 in herpes simplex
virus 1 (HSV-1)-infected keratinocytes (7). More recently, we
showed that pJAK2(1001–1013) inhibited the replication of vac-
cinia virus and encephalomyocarditis virus in cell culture via
inhibition of SOCS1 (3). In the same study, pJAK2(1001–1013)
protected mice against lethal vaccinia and encephalomyocarditis
virus infection.
It was recently shown that influenza A virus PR8 H1N1 infec-
tion of a human alveolar epithelial cell line induced early expres-
sion of SOCS1 and later expression of SOCS3 (8). SOCS expres-
sion correlated with virus refractiveness to type I IFN therapy
of infected cells. Similar results were obtained by others where
it was shown that the virus induction of SOCS1 and SOCS3
occurred via a retinoic acid-inducible gene 1/type 1 IFN receptor
IFNAR1-dependent pathway (9).
Although there is interest in various innate response mecha-
nisms to influenza virus infection, including the IFN response,
there is no concerted or serious effort to use IFNs as thera-
peutics, perhaps because there is no obvious convenient use of
these proteins on a large scale. Currently, virus neuraminidase
inhibitors, particularly oseltamivir (Tamiflu), are the most widely
used influenza therapeutics where their therapeutic efficacy has
been variable, with the demonstration of oseltamivir resistance
associated with neuraminidase mutations (10). Along with the
gastrointestinal side effects, neuraminidase inhibitors have also
been associated with neuropsychiatric effects (11).
In this report, we determined the ability of the SOCS1 antag-
onist to protect mice against a lethal dose of influenza A/PR8
(H1N1) infection.We further determined if protective effectswere
accompanied by an adjuvant effect in enhancing the innate and
adaptive immune responses to influenza virus infection. SOCS
proteins function intracellularly only in cells that produce them
and are thus not secreted to exert intercellular effects. Accord-
ingly, we have established that the SOCS1 antagonist has to be
internalized in order to interact with and inhibit both constitutive
and induced SOCS1. SOCS1 antagonist pJAK2(1001–1013) was,
thus, synthesized with an attached lipophilic (lipo) palmitate for
cell penetration (3) in studies reported here.
MATERIALS AND METHODS
Peptide Synthesis
SOCS1/3 antagonist, its control peptide, as well as influenza
M2e peptide were synthesized using fluorenylmethyloxycarbonyl
chemistry, as previously described (12). A lipophilic group
(palmitoyl-lysine) for cell penetration was added to the N-
terminus as a last step of synthesis, using a semi-automated
protocol. The sequence of SOCS1/3 antagonist peptide is,
LPQDKEpYYKVKEP (pJAK2). The control peptide that has
the tyrosines replaced by alanines and lacks biological activ-
ity has the following sequence, LPQDKEAAKVKEP (JAK2A).
Influenza A virus M2e peptide had the following sequence,
MSLLTEVETPTRNGWECRCSDSSD. Peptides were dissolved in
DMSO followed by dilution in PBS.
Cell Culture and Antiviral Assays
MDCK cells were grown in DMEM with 10% FBS and antibi-
otics. These cells were infected with influenza A/PR8 virus (103
TCID50/ml), and incubated for 1 h at 35°C. The media was
removed and replaced with DMEM with FBS and the cells were
incubated for an additional 24 h at 35°C. The cells were stained
with crystal violet and absorbance was measured.
Mice
All animal protocols were approved by the Institutional Animal
Care and Use Committee at the University of Florida. Female
C57BL/6 mice (6–8weeks old) were purchased from The Jackson
Laboratory (BarHarbor,ME, USA). Peptides dissolved in PBS in a
volume of 100μl were administered i.p. Mouse adapted influenza
A/PR8 virus (10 LD50 pfu) was administered intranasally taken
in a volume of 10μl, with 5μl delivered in each of the nostrils
of a lightly anesthetized mouse. Following infection, mice were
observed daily for signs of disease, such as lethargy, ruffled hair,
weight loss, and eye secretions. Moribund mice were euthanized
and counted as dead.
Measurement of Influenza A Virus-Specific
Cellular and Humoral Immune Responses
Spleens from naive or mice immunized intraperitoneally
with M2e peptide (50μg) in the presence of 200μg of
pJAK2(1001–1013), or control peptide (scram) were harvested
after 4 weeks and homogenized to single-cell suspension.
Splenocytes (105 cells/well) were incubated with medium
alone or medium containing M2e peptide (50μg) at 37°C for
72 h. CellTiter Aqueous One Cell Proliferation Assay reagent
(Promega) was added and the absorbance was measured.
Blood was drawn from naïve mice or those immunized with
M2e peptide in the presence of pJAK2 or control peptide after 2
or 3weeks.Microtiter plates coated withM2e peptide (10μg/well)
were blocked with PBS containing 5% FBS for 2 h at room
temperature. Mouse serum was serially diluted (0.1ml) in PBS
containing 0.1% Tween 20 (wash buffer). Plates were incubated
for 2 h at room temperature and washed three times with wash
buffer. Peroxidase-conjugated goat anti-mouse IgG (Santa Cruz
Biotechnology), diluted in a volume of 0.1ml, was added to each
well, incubated for 1 h, and washed five times with wash buffer. o-
Phenylenediamine (OPD) (0.1ml) was added and incubated for
15min. The reaction was stopped by addition of 50μl 3N HCl.
The OD at 490 nmwas determined using amicrotiter plate reader.
Alexa Fluor 647 Labeling and Detection of
Cell Penetration
Alexa Fluor 647 was conjugated to lipo-pJAK2(1001–1013)
according to the manufacturer’s (Invitrogen) instructions. Mice
were injected i.p. with 15μg Alexa Fluor 647-labeled lipo-
pJAK2(1010–1013) or an equivalent amount of Alexa Fluor alone.
Twohours later, different organswere harvested and viewed under
a Xenogen IVIS fluorescence imager. Cells isolated from spleen,
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lymph nodes, and peritoneal cavity were labeled with antibodies
toCD4+, CD8+, B220+, andCD11b+ immune cells and analyzed
by flow cytometry.
Statistical Analysis
All experimental data were analyzed for statistical significance by
Student’s t-test. For mice studies, Kaplan–Meier survival curve
and log-rank test were used. GraphPad Prism from GraphPad
Software (San Diego, CA, USA) was used for statistical analysis.
RESULTS
To determine if lipo-pJAK2(1001–1013) possessed anti-influenza
virus activity in cell culture, we first incubated the antagonist
with MDCK cells for 18 h. As a control, we similarly treated cells
with the SOCS1 antagonist control peptide where the tyrosines
at residues 1007 and 1008 of the peptide were replaced with
alanines. Phosphorylated tyrosine 1007 has been shown to play
an essential role in activated JAK2(pJAK2) enzymatic activity (2).
We have shown that wild-type pJAK2(1001–1013) interacted with
KIR of SOCS1muchmore effectively than the alanine-substituted
JAK2(1001–1013)2A and possessed antiviral activity against vac-
cinia virus, while the substituted peptide failed to antagonize
SOCS1 in cell cultures and in mice infected with the virus (3).
As shown inFigure 1A, the SOCS antagonist but not the control
peptide blocked influenza PR8 virus replication in the MDCK
cells as reflected by lack of virus induced cytopathogenic effect
(CPE) in antagonist-treated cells. Specifically, antagonist-treated
cells infected with a 103 tissue culture infectivity doses of virus per
milliliter (103 TCID50/ml) showed 85% survival, similar to that of
untreated cells, while untreated virus-infected cells showed 18%
survival. Alanine-substituted control peptide treated cells showed
40% survival. These tissue culture results, thus, suggest that the
SOCS1 antagonist could potentially show antiviral activity against
influenza virus infection in mice.
As shown in Figure 1B, the SOCS1 antagonist completely
protected C57BL/6 mice from a 10 LD50 dose of influenza virus,
while the control peptide treated mice all died by day 9, similar
to PBS-treated mice. The surviving mice did not show any signs
of illness for four additional weeks until the completion of the
study. Treatment involved IP injection of 200μg peptide daily
for 1week, beginning 1 day post-intranasal infection. Thus, the
SOCS1 antagonist possessed potent therapeutic efficacy against
mice infected with a lethal dose of influenza virus.
In order to obtain some insight into the ability of the SOCS1
antagonist to protect mice against infection, we focused on sev-
eral parameters that reflect the degree of morbidity. SOCS1
antagonist-treated mice showed no drop in body temperature,
while control mice experienced approximately a 5% drop in tem-
perature at days 4–8 post-infection (Figure 2A). We assessed
clinical scores on the well-being of the mice by the following
scale: 1, ruffled hair, hunched posture; 2, 1+ lethargic; 3, weight
loss; 4, moribund; and 5, death. As shown in Figure 2B, control
mice showed increasing clinical scores over time, while the clinical
scores of SOCS1 antagonist-treated mice stayed the same. Consis-
tent with all of this, control mice experienced a dramatic loss of
weight due to infection, approaching 15% by day 7 (Figure 2C),
FIGURE 1 | SOCS antagonist protects mice against influenza A virus
infection. (A) MDCK cells were infected with influenza A virus in the presence
of SOCS1 antagonist or its control peptide. After 24 h of infection, cells were
stained with crystal violet and the cell survival was measured. The significance
of differences was p= 0.001, p= 0.006, and p= 0.001 for virus only, pJAK2
and control peptide, respectively, versus media only. (B) Mice (C57BL/6,
n= 5) were infected intranasally with 10 LD50 of influenza A PR/8 (H1N1)
virus. Starting with day 1, PBS, or 200μg each of SOCS antagonist, or the
alanine-substituted antagonist control peptide were injected i.p. daily for
1week. Palmitate was attached to all peptides for cell penetration. Survival of
mice was followed. p Value of <0.01 was observed for the SOCS antagonist
versus the control peptide. For more details on the peptides, see Section
“Materials and Methods.”
while antagonist-treatedmice gainedweight. The antagonist, thus,
protected mice against the symptoms associated with influenza
virus infection.
In addition to protection in terms of morbidity and mortality,
we were interested in determining if the SOCS1 antagonist pos-
sessed adjuvant effects against the influenza virus. We focused on
the conserved extracellular domain of the matrix protein 2 (M2e),
which is highly conserved across the various human influenza A
virus strains. We synthesized the 24-amino acid M2e consensus
sequence and injected mice IP with 200μgM2e along with 200μg
SOCS1 antagonist or antagonist control peptide. Spleens were
removed after 4weeks and the cells were incubated with M2e
(50μg/ml) for 72 h and cellular proliferation was assessed via
the Cell Titer Aqueous One Cell proliferation assay (Promega,
Madison, WI, USA). As shown in Figure 3A, proliferation was
observed only inmice that were injected withM2e and the SOCS1
antagonist. The SOCS1 antagonist control-treated mice showed a
profile similar to that of naïve mice. Serum from the same mice
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FIGURE 2 | SOCS antagonist protects against the onset of symptoms
in influenza A virus infection. C57BL/6 mice were infected intranasally as
in Figure 1 on day 0 with 10 LD50 of influenza A PR/8 virus. Starting with
day 1, daily injections of PBS or pJAK2 (200μg) were given i.p. All the
PBS-injected mice were dead by day 9, while the pJAK2-treated mice
survived the virus challenge. Changes in body temperature in Fahrenheit are
indicated in (A). The p value between pJAK2 peptide versus PBS was 0.001.
Clinical score (see text) is shown in (B), where p= 0.002 between pJAK2-
versus PBS-treated mice. Body weight in grams is recorded in (C). The
significance of difference between pJAK2 and PBS is p= 0.002.
showed an antibody response to M2e only when the mice were
also injected with SOCS1 antagonist (Figure 3B). The SOCS1
antagonist, thus, possessed adjuvancy at the cellular and humoral
level of immune response to the M2e universal influenza virus
antigen.
Using Alexa Fluor 647 conjugated-lipo-pJAK2(1001–1013)
(AF-pJAK2), we assessed organ and immune cell presence of
the antagonist. Specifically, C57BL/6 mice were injected IP with
200μg AF-pJAK2 and 2 h later, organs and tissues were harvested
and analyzed for the presence of AF-pJAK2 in brain, liver, kidney,
and spleen (Figure 4A). Control organs from mice-injected with
Alexa 647 alone showed relative absence of the fluorochrome.
Cell sorting showed the presence of AF-pJAK2 in CD4+, CD8+,
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FIGURE 3 | pJAK2(1001–1013) exhibits adjuvant properties at both
cellular and humoral levels. (A) Spleens were harvested from C57BL/6
mice (n= 3) 4weeks after immunization with M2e as an antigen and
treatment with pJAK2 or the control peptide. Naïve mice were included as a
control. Splenocytes (5105 cells per well) in microtiter plates were
incubated with or without M2e (50μg/ml) for 72 h. CellTiter Aqueous One Cell
Proliferation Assay reagent was added and absorbance was read. p Value of
<0.01 was observed between pJAK2-treated and naïve mice. (B) Mice were
immunized using M2e as an antigen in the presence of pJAK2 peptide or the
control peptide. After 2 and 3weeks, blood was drawn from the mice and
measured for the presence of M2e-specific antibodies in an ELISA format.
The values represent average with SD. p Value of <0.05 was obtained for the
SOCS antagonist versus the control peptide.
B220+, and CD11b+ cells of the spleen, lymph node, and antigen-
presenting cells relative to the Alexa 647 control (Figure 4B).
Thus, lipo-pJAK2(1001–1013) showed wide organ and immune
cell presence in treated mice.
DISCUSSION
The absolute critical importance of SOCS in regulation of
cytokines, such as the IFNs, is underscored by the demonstration
that homozygous knockout of the SOCS1 gene in mice results in
lethal neonatal inflammatory disease due in large part to unreg-
ulated IFNγ activity (13). Thus, most JAK/STAT signaling that is
related to innate and adaptive immunity also temporally activates
genes, such as SOCS1, to mitigate against prolonged expression
or overexpression of cytokines that might result in inflammatory
damage to the individual. Both SOCS1 and SOCS3 appear to
play important roles in influenza virus infection at the cellu-
lar level. Specifically, it has recently been shown that influenza
A/PR8 infection of a human alveolar epithelial cell line induced
early expression of SOCS1 and later expression of SOCS3 (8, 9).
Although SOCS expression correlated with virus refractiveness to
type I IFN therapy of infected cells, a definitive causal relationship
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FIGURE 4 | Tissue and immune cell localization of Alexa Fluor 647
conjugated lipo-pJAK2 (AF-pJAK2) peptide. Lipo-pJak2 was conjugated
to the fluorochrome Alexa 647 (Invitrogen). AF-pJAK2 or unconjugated
fluorochrome was injected into C57BL/6 mice i.p., followed by sacrifice of the
mice 2 h later. Brain, liver, kidney, spleen, lymph node, and peritoneal cells
were subsequently isolated. (A) AF-pJAK2 incorporation into the brain, liver,
kidney, and spleen of mice receiving AF-pJAK2 i.p (left) in contrast to mice
receiving unconjugated Alexa 647 (FC, right) using a Xenogen IVIS
Fluorescence Imager. (B) AF-pJAK2 is incorporated into immune cells.
Histograms showing CD4+, CD8+, B220+, and CD11b+ leukocytes
present within the spleen, lymph node, and peritoneal cavity of
AF-pJAK2-injected mice that stained positive for AF-647 (red) when
compared to leukocytes isolated from mice receiving unconjugated AF-647
i.p. (uncolored histogram). Data are representative of two independent
experiments with four mice in each group.
was not shown. Additionally, there were no animal model studies
done that actually showed that induction of SOCS played a role in
influenza virus pathogenesis.
A well-recognized but not fully understood aspect of IFN func-
tion in cells is that most cells constitutively produce low levels
of intracellular IFNβ that have been shown to play a role in
induction of an antiviral state in cells treated with type I and
type II IFNs (5, 6). pJAK2(1001–1013) increased the level of
intracellular IFNβ in cells in which it induced the antiviral state.
In addition, pJAK2(1001–1013) enhanced STAT1α transcription
factor activation and synergized with IFNγ mimetic at the level
of transcription to induce gene activation through the GAS pro-
moter (3). This provides insight into the mechanistic effects
of the SOCS antagonist at the level of signal transduction and
gene activation.
In addition to SOCS, regulatory T cells are an important
regulatory arm of the immune system (14, 15). We and others
have shown that there is cross-talk between these two regulatory
arms (15). Importantly, we showed that there was a hierarchy
between the two systems, where SOCS1 is required for a func-
tional peripheral regulatory T cell system. This suggests that the
SOCS1/3 antagonist controls regulatory T cells via its regulation
of the SOCS system. Our SOCS antagonist should, thus, have
potential for direct treatment of influenza virus infections, but also
should play a role in enhancement of immunogenicity of universal
influenza virus antigens such as the M2e polypeptide.
Given that our SOCS1/3 antagonist is effective against a broad
group of viruses, such as HSV-1, vaccinia virus, EMC virus, and
here against influenza virus, we feel that it should be a candidate
for treatment of virus infections in general, including that of
the Ebola virus and members of the Flaviviridae family. It has
recently been shown, for example, that Ebola virus infection of the
human HEK293 cell line results in induction of SOCS1 (16). Two
members of the Flaviviridae family of viruses, dengue virus and
West Nile virus, similarly induce SOCS, specifically SOCS1 and
SOCS3, and this has been considered as potentially inhibiting the
IFN response in these infections (17).
A recent study showed that the SOCS1 antagonist enhanced
antigen presentation of human dendritic cells for increased cyto-
toxic T cell response against human gastric cancer cells (18). This
broadens the potential use of pJAK2(1001–1013) beyond the role
of an antiviral, and also as an enhancer of the immune system in
host defense against cancer, as we have shown previously (19). In a
general sense, it would suggest that SOCS, such as SOCS1, should
be considered in circumstances where increased immune activity
is desirable against infectious as well as non-infectious diseases
such as cancer.
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